checkAd

     141  0 Kommentare Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services - Seite 2

    About EXPAREL
    EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

    Important Safety Information for Patients
    EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation, and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.

    CONTACT: Company Contact:
    Pacira BioSciences, Inc.
    Susan Mesco, (973) 451-4030
    Susan.Mesco@pacira.com
    
    Media Contact:
    Coyne Public Relations
    Alyssa Schneider, (973) 588-2270
    aschneider@coynepr.com
    Seite 2 von 2




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services - Seite 2 The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical painPARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) - Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid …

    Schreibe Deinen Kommentar

    Disclaimer